G7 HPLC. Used as an aid in the detection and presumptive identification of abnormal hemoglobins in whole blood.
Published April 17, 2013 · Recall initiated: August 18, 2010
Summary
FDA records medical device Class III recall Z-1075-2013, published April 17, 2013 and initiated August 18, 2010. Recalling firm: Tosoh Bioscience Inc; Status: Terminated; Reported quantity: 633; Lot: 11103403, 11103503, 10942812, 11514801, 11674706, 11313707, 11273006, 10952212, 12266302, 10872910R, 12506812, 11273206, 12678203, 12728404, 12075007, 12205211, 12627811, 12668403, 12708704, 10361310R, 10792008R. Class III means the product is not likely to cause adverse health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
The Beta-thalessemia Mode of the G7 Analyzer-Beta Thalassemia Mode is an automated High Performance Liquid Chromatography (HPLC) system that separates and reports HbF and HbA2 quantitative percentages in whole blood. The firm received complaints that the A2 peak could not be detected with the G7 Beta-thalessemia columns.
What to do
Voluntary: Firm initiated
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Tosoh Bioscience Inc
- Distributor
- Worldwide Distribution-USA (nationwide) including DC, Puerto Rico, Virgin Islands and the states of AK, AL, AR, AZ, CA, CO, CT, DE, FL, GA, IA, ID, IL, IN, KS, KY, LA, MA, MD, MI, MN, MO, MS, MT, NC, ND, NE, NH, NJ, NV, NY, OH, OK, OR, PA, PR, RI, SC, SD, TN, TX, UT, VA, VT, WA, WI and WV, and the countries of Canada, Columbia, Chile, Brazil, and Jamaica.
- Lot
- 11103403, 11103503, 10942812, 11514801, 11674706, 11313707, 11273006, 10952212, 12266302, 10872910R, 12506812, 11273206, 12678203, 12728404, 12075007, 12205211, 12627811, 12668403, 12708704, 10361310R, 10792008R.
- Risk classification
- Class III
- Area (FDA)
- device
- Country
- United States
Related recalls
- FDAST AIA-Pack Testosterone, IN VITRO DIAGNOSTIC USE ONLY for the quantitative measurement of testosterone inJuly 22, 2026
- FDATosoh Bioscience AIA-PACK BHCG Calibration Verification Test Set-In Vitro Diagnostic for BHCG-pregnancy PartSeptember 23, 2020
- FDAAIA-PACK Folate (FOL) is designed for IN VITRO DIAGNOSTIC USE ONLY for the quantitative measurement of folateJanuary 2, 2019
- FDAST AIA-PACK ACTH (ACTH: Adrenocorticotropic Hormone) is designed for IN VITRO DIAGNOSTIC USE ONLY for theJanuary 2, 2019
- FDADade(R) Actin(R) FSL Activated PTT Reagent. For use in the determination of the activated partialApril 17, 2013
- FDAKerr Maxcem Elite, self-etch/self-adhesive resin cement; Intro Kit Part No. 34417; DMC 0446 Rev 0. Used forApril 17, 2013
Questions about this recall
Was G7 HPLC. Used as an aid in the detection and presumptive identification of abnormal hemoglobins in whole blood. recalled?
Yes. FDA published recall Z-1075-2013 on April 17, 2013. Reported hazard: The Beta-thalessemia Mode of the G7 Analyzer-Beta Thalassemia Mode is an automated High Performance Liquid Chromatography (HPLC) system that separates and reports HbF and HbA2 quantitative percentages in whole blood. The firm received complaints that the A2 peak could not be detected with the G7 Beta-thalessemia columns.
What should I do if I have this product?
Voluntary: Firm initiated